AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
Tempus AI vs Aidoc

Tempus AI

Aidoc

Verdict by Category

Detailed category analysis is not available for this comparison.

View Tempus AI View Aidoc

Detailed Comparison

Feature

Tempus AI

Aidoc

Pricing

CustomTempus operates multiple revenue streams with different access models. Clinical genomic tests (xT, xG, xR, xF, xE) are ordered by physicians through the standard laboratory test ordering process. Pricing varies by test type and is typically covered by insurance for oncology patients. Tempus works directly with health systems to integrate ordering into EHR workflows. Enterprise data platform access, Algos population health analytics, and biopharma research partnerships are priced through custom enterprise licensing agreements. Biopharma companies license Tempus's de-identified patient datasets and analytical services for drug development and clinical trial design. Tempus is publicly traded on NASDAQ (ticker: TEM) since June 2024. Investor and enterprise partnership inquiries can be directed through tempus.com.

CustomAidoc operates on enterprise contracts with hospitals and health systems — there is no published pricing or self-serve option. Pricing is customized based on hospital size, imaging volume, number of AI algorithms deployed, and integration complexity. Health systems engage through Aidoc's enterprise sales team, who assess needs, design a deployment plan, and structure a contract that typically includes implementation, onboarding, and ongoing support. Aidoc's BRIDGE framework with NVIDIA supports scalable rollout across multi-site health systems. Contact Aidoc directly at aidoc.com to request a demo or begin the enterprise procurement process.

Tempus AI Pros & Cons

Pros

Publicly traded (NASDAQ: TEM) — one of the most credible precision medicine AI companies
7M+ de-identified patient records — one of the world's largest clinical-molecular datasets
Comprehensive genomic testing across 6 test types covering all major oncology applications
Tempus One AI provides real-time clinical insights at the point of care
TIME Trial dramatically improves clinical trial matching and enrollment rates
3,800+ employees and $8.79B total capital raised since founding
Expanding beyond oncology into neuropsychiatry, cardiology, and infectious disease

Cons

Enterprise and institutional pricing — not accessible to individual clinicians or small practices
Focused primarily on oncology and genomics — not a general-purpose clinical AI tool
Genomic test turnaround requires laboratory processing time
Data platform access and licensing requires formal agreements
Some AI insights require institutional genomic data infrastructure to fully leverage

Aidoc Pros & Cons

Pros

Deployed in nearly 2,000 hospitals — the most widely adopted AI radiology platform globally
60M+ patient cases analyzed annually — proven at massive scale
$534M raised — one of the best-funded medical AI companies in the world
Dozens of FDA clearances — most extensively cleared AI imaging portfolio available
PACS-agnostic — works with any existing radiology infrastructure
Gartner Cool Vendor and named in multiple industry AI leadership reports
CARE1 foundation model and BRIDGE/NVIDIA framework for next-gen AI deployment